Citius Oncology, Stock Fundamentals
| CTOR Stock | 0.94 0.06 6.00% |
Citius Oncology, fundamentals help investors to digest information that contributes to Citius Oncology,'s financial success or failures. It also enables traders to predict the movement of Citius Stock. The fundamental analysis module provides a way to measure Citius Oncology,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Citius Oncology, stock.
Citius |
Citius Oncology, Company Price To Book Analysis
Citius Oncology,'s Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Citius Oncology, Price To Book | 4.55 X |
Most of Citius Oncology,'s fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Citius Oncology, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Citius Oncology, has a Price To Book of 4.5515 times. This is much higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The price to book for all United States stocks is notably lower than that of the firm.
Citius Oncology, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Citius Oncology,'s current stock value. Our valuation model uses many indicators to compare Citius Oncology, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Citius Oncology, competition to find correlations between indicators driving Citius Oncology,'s intrinsic value. More Info.Citius Oncology, is rated below average in current valuation category among its peers. It also is rated below average in shares outstanding category among its peers creating about 0.02 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for Citius Oncology, is roughly 58.11 . As of 11/28/2024, Common Stock Shares Outstanding is likely to drop to about 57 M. Comparative valuation analysis is a catch-all technique that is used if you cannot value Citius Oncology, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Citius Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Oncology,'s direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Oncology, could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics of similar companies.Citius Oncology, is currently under evaluation in price to book category among its peers.
Citius Fundamentals
| Current Valuation | 116.23 M | ||||
| Shares Outstanding | 2 M | ||||
| Number Of Shares Shorted | 39.42 K | ||||
| Price To Book | 4.55 X | ||||
| Market Capitalization | 116.23 M |
About Citius Oncology, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Oncology,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.72 | ESPR | Esperion Therapeutics | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.67 | FLGC | Flora Growth Corp | PairCorr |
| 0.6 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.